Tue Oct 01 10:17:22 UTC 2024: ## Ironwood Pharmaceuticals Earnings Upgraded, Analyst Opinions Mixed

**Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)** saw its Q4 2024 earnings per share estimates raised by Leerink Partners, with analyst F. Khurshid predicting a profit of $0.10 per share, up from the previous estimate of $0.09. Leerink Partners currently maintains a “Hold” rating on the stock.

The consensus estimate for the full year remains at $0.24 per share. Leerink also provided estimates for future quarters, forecasting $0.05 EPS for Q3 2025, $0.05 EPS for Q4 2025, $0.17 EPS for FY2025, and $0.45 EPS for FY2026.

Other analysts have issued mixed opinions on Ironwood. While StockNews.com upgraded the stock from “Hold” to “Buy,” Capital One Financial downgraded it from “Overweight” to “Equal Weight” and lowered its price target. Wells Fargo, Craig Hallum, and Leerink Partners all reduced their price targets while maintaining varying levels of optimism.

Overall, the company has an “Moderate Buy” rating with an average price target of $12.17, based on data from MarketBeat.com.

The company opened at $4.12 on Tuesday, with a market capitalization of $644.90 million. Ironwood focuses on developing and commercializing gastrointestinal (GI) products, primarily linaclotide, a treatment for irritable bowel syndrome and chronic constipation.

Institutional investors have been active in the stock, with Vanguard Group Inc., Armistice Capital LLC, Pacer Advisors Inc., Kynam Capital Management LP, and Renaissance Technologies LLC all adjusting their holdings in recent quarters.

Ironwood continues to navigate a complex market, facing both bullish and bearish opinions from analysts. The company’s future performance will depend heavily on the success of its products and its ability to maintain a competitive edge in the GI market.

Read More